Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03986762 · ClinicalTrials.gov registry record · Phase 1

Open Label Pharmaco- Magnetic Resonance Spectrography (MRS) Study of Clavulanic Acid

A Phase 1 study of Cocaine-Related Disorders and Cocaine Dependence, in Remission, sponsored by Temple University.

Completed
Registry status
Phase 1
Development phase
9
Enrollment target
1
Study location

NCT03986762: Completed Phase 1 study of Cocaine-Related Disorders and Cocaine Dependence, in Remission, sponsored by Temple University.

NCT03986762 is a Phase 1 study of Cocaine-Related Disorders and Cocaine Dependence, in Remission that has completed, run by Temple University. The registered enrollment target is 9 participants, below the 64-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03986762, a Phase 1 study of Cocaine-Related Disorders and Cocaine Dependence, in Remission, has completed, sponsored by Temple University.

COMPLETED
Registry status
Phase 1
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

The main purpose of this study is to determine how the study drug, clavulanic acid, affects glutamate in the brain using Magnetic Resonance (MR/MRI) scans. In this study, subjects will receive the study drug, clavulanic acid and undergo 4 MRI scans. This is being studied to determine the correct dosing of clavulanic acid, and to gather data so future studies can be done to find out if this drug is helpful in treating cocaine dependence. Currently, there is no available medication treatment for cocaine dependence.

Primary Outcome

Change in brain glutamate concentration at Day 10-17 compared with baseline.

Conditions Studied

Cocaine-Related Disorders Cocaine Dependence, in Remission Cocaine Abuse, in Remission

Interventions

  • DRUG Clavulanic Acid

Study Locations (1)

Pennsylvania

  • Episcopal Hospital Medical Arts Building - Philadelphia

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2019-03-12
Est. Completion 2019-12-20
Phase Phase 1
Temple University

163 total trials

What the finished NCT03986762 record still lists

NCT03986762 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 64-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (86% lower).

The record links to 3 conditions, with Cocaine-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Clavulanic Acid is the first listed.

NCT03986762 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03986762 about?

NCT03986762 is a clinical study titled "Open Label Pharmaco- Magnetic Resonance Spectrography (MRS) Study of Clavulanic Acid". The main purpose of this study is to determine how the study drug, clavulanic acid, affects glutamate in the brain using Magnetic Resonance (MR/MRI) scans. In this study, subjects will receive the study drug, clavulanic acid and undergo 4 MRI scans. This is being studied to determine the correct dos...

What is the current status of trial NCT03986762?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2019-03-12. Estimated completion is 2019-12-20.

What conditions does trial NCT03986762 study?

This clinical trial studies the following conditions: Cocaine-Related Disorders, Cocaine Dependence, in Remission, Cocaine Abuse, in Remission.

What interventions are being tested in trial NCT03986762?

The interventions under investigation include: Clavulanic Acid (DRUG).

Who is sponsoring clinical trial NCT03986762?

This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03986762 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cocaine-Related Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03986762's enrollment target sits among peer trials

9 14th of 15 higher than 2 of 15 other Cocaine-Related Disorders trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cocaine-Related Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03986762, the US trial registry maintained by the National Library of Medicine. NCT03986762 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.